BridgeBio's oral infigratinib gets US FDA Priority Review in achondroplasia

The US FDA has granted Priority Review to BridgeBio Pharma's oral infigratinib for treating children with achondroplasia, targeting a decision by February 4, 2027. If approved, infigratinib would become the first oral therapy for this condition, currently treated by injectable C-type natriuretic peptide analogs.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.